OncologyJohnson & Johnson
Johnson & Johnson Reports Five-Year POLLUX Data for Darzalex in Relapsed Myeloma
BMI
Biotechnology Media Insights
Editorial Team · August 5, 2023
J&J presents five-year follow-up data from POLLUX trial showing durable benefit of Darzalex plus lenalidomide and dexamethasone in relapsed/refractory myeloma.
Johnson & Johnson today presented five-year follow-up data from the Phase 3 POLLUX trial evaluating Darzalex (daratumumab) plus lenalidomide and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma. The data showed that the progression-free survival benefit of DRd was maintained at five years.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.